Advertisement

Updated June 19th, 2021 at 21:25 IST

Delta variant may become dominant COVID strain, warns US CDC; stresses on vaccination

The Delta strain of SARS-CoV-2 is likely to become the dominant strain of coronavirus in the United States, the Director of CDC stated on June 19.

Reported by: Riya Baibhawi
Delta
Image: AP  | Image:self
Advertisement

The Delta strain of SARS-CoV-2 is likely to become the dominant strain of coronavirus in the United States, Director of Centre for Disease Control and Prevention (CDC), Rochelle Walensky said on June 19. Speaking at an interview with ABC network, the top health expert said that the B.1.617.2 variant was “hyper transmissible”. However softening the blow, she asserted that the vaccines were “working well” and asked Americans to get their two shots to be immunized against the “worrisome” mutation.

“So I would encourage all Americans, get your first shot, and when you’re due for your second, get your second shot and you’ll be protected against this Delta variant,” she added in the interview.

'Variant of concern' 

The Delta variant, which was first identified in India, has jumped international borders to spread across more than 80 countries, a World Health Organisation report disclosed. Earlier, the CDC raised the strain from “variant of interest” to “variant of concern” implying that it may carry the risk of severe illness. As per the Federal health agency, the Delta variant of coronavirus accounted for 10 per cent of total infections on the American territory.

On Friday, World Health Organization’s chief scientist Soumya Swaminathan said at a news conference that because of its significantly increased transmissibility the delta variant is now on the way to becoming the dominant variant worldwide. She added, that scientists still need more data on the variant, including its impact on the efficacy of COVID-19 vaccines. Previously, she had stated that herd immunity was unlikely to be achieved in 2021. 

The WHO chief scientists also expressed concern about the German company CureVac’s failed trials after the jab proved to be only 47 per cent effective in a clinical trial with 40,000 participants. The company cited the spread of the variants as the reason for reduced protection from the vaccine. With mRNA vaccines from Pfizer and BioNTech and Moderna giving 90 per cent above efficacy rate, Swaminathan stated that WHO expected robust protection from the CureVac’s candidate.

Image: AP 

Advertisement

Published June 19th, 2021 at 21:19 IST

Your Voice. Now Direct.

Send us your views, we’ll publish them. This section is moderated.

Advertisement
Advertisement

Trending Quicks

Mamaearth
a few seconds ago
MEA Responds To China’s Comment On Sikh Separatist Gurupatwant Singh Pannun
a few seconds ago
Mukhtar Ansari Death
a minute ago
Dhara Gujjar
2 minutes ago
The ICJ has ordered Israel to ensure the smooth flow of aid to the people of Gaza.
8 minutes ago
UFC Exclusive Erin Blanchfield
10 minutes ago
Indian pharma sector
12 minutes ago
WWE Bloodline
12 minutes ago
Ramya on Uttarakaanda sets
17 minutes ago
Virat Kohli and Glenn Maxwell
18 minutes ago
Maharashtra Politics: Did Govinda Say Congress Ignored Him For 13 Years?
19 minutes ago
Jailed Gangster Mukhtar Ansari Passes Away
21 minutes ago
Torrent Power
23 minutes ago
Advertisement
Advertisement
Advertisement
Whatsapp logo